Final research-target dose 2.4 mg + 2.4 mg weekly Titration length ~16 weeks Trial duration 68 weeks (REDEFINE 1 / REDEFINE 2) Route Subcutaneous, once weekly Compound Delivery: 2.4 mg / 2.4 mg Maintenance Pre-blended vials simplify weekly administration to a single injection but lock the ratio at 1:1
Because Momentum and Elevate Plans include a larger quantity of medication, we strongly recommend that new patients first try a Monthly or Tier Plan to ensure tolerance and response to the specific formulation
42,43 The current guidelines of the American Association of Clinical Endocrinologists 44 recommend using GLP-1 receptor agonists with caution if they are needed in patients with type 2 diabetes who have a history of pancreatitis
Patients should maintain adequate fluid intake based on individual needs, with attention to urine color (pale yellow indicates adequate hydration)
Effective Weight Loss: Clinical trials with injectable Tirzepatide have shown impressive weight loss results, and our compounded oral Tirzepatid aims to provide similar benefits, just without the needles